Intravenous Immunoglobulin and Rituximab in HLA Highly Sensitized Kidney Transplant Recipients

Induction immunosuppressive therapy with intravenous immunoglobulin and rituximab is effective; outcomes demonstrate an excellent patient and allograft survival and allograft function over the follow-up period.